# A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy

> **NCT02167139** · PHASE3 · COMPLETED · sponsor: **Samsung Bioepis Co., Ltd.** · enrollment: 544 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** Humira (adalimumab)
- **DRUG:** SB5 (proposed biosimilar to adalimumab)

## Key facts

- **NCT ID:** NCT02167139
- **Lead sponsor:** Samsung Bioepis Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2015-04
- **Final completion:** 2015-10
- **Target enrollment:** 544 (ACTUAL)
- **Last updated:** 2017-08-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02167139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02167139, "A Study Comparing SB5 to Humira® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate Therapy". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT02167139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*